All Evaluable Patients Achieved Improvements in Multiple Hallmarks of 

MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA's Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported promising new interim safety and efficacy data from the company's MyPEAK™-1 Phase 1b/2 clinical trial of TN-201. TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic cardiomyopathy (HCM), a condition caused by insufficient levels of myosin-binding protein C (MyBP-C).

Data shared today build on previously presented interim results, now with 78-104 weeks of follow-up for the three patients dosed with TN-201 gene therapy at 3E13 vg/kg (Cohort 1), and 26-52 weeks of follow-up for four patients dosed with TN-201 at 6E13 vg/kg (Cohort 2). Among the new findings as of the May 2026 data cut off, the six patients evaluable for efficacy endpoints demonstrated improvements in multiple clinical parameters of disease including echocardiographic measures of hypertrophy, and one or more measures of symptom burden. In addition, three patients, including two from the high-dose cohort, had improvements in exercise capacity by at least one measure.